Focus on ASCO presentation on June 1 for full data and any regulatory updates. The positive combination data supports azenosertib's broader potential, but the stock's history of large post-event reversals suggests caution on extended holding.
Price Chart
Executive Summary
Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% ORR and 7.3-month median PFS in all-comers, and 50% ORR at the 250 mg intermittent dose. The data will be presented at ASCO 2026. The company also reported a Q1 2026 EPS miss of $-0.50 versus consensus $-0.46, though this is secondary for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Phase 1b MUIR trial of azenosertib + paclitaxel showed 39% ORR and 7.3-month median PFS in all-comer PROC (n=46).
- At the 250 mg 5:2 intermittent dose (n=12), ORR was 50% with median DOR of 9.2 months.
- Clinical activity was comparable in Cyclin E1-positive and negative patients.
- Manageable safety: Grade ≥3 neutropenia 30.4%, anemia 19.6%.
- Data to be presented at ASCO 2026 on June 1.
- Q1 2026 EPS of -$0.50 missed consensus of -$0.46 (-8.7% miss).
Financial Impact
Clinical data positive but early; EPS miss of $0.04 is immaterial for pre-revenue biotech; stock likely driven by ASCO data.
Risk Factors
- Phase 1b data not yet confirmed in larger Phase 3 trials.
- Historical volatility: previous high-score calls on ZNTL have shown negative T+20 outcomes.
- Competition from other WEE1 inhibitors and chemotherapy combos.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.55 (+31.31%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.55 (+28.51%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.55 (−32.13%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.55 (−35.57%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.55 (−37.32%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.55 (−37.32%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.55 (−40.54%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.55 (−40.54%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.55 (−36.22%) |
Apr 17, 2026 23w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.55 (−45.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access